ACM
ADAR1 Capital Management Portfolio holdings
AUM
$616M
This Quarter Return
+12.23%
1 Year Return
+26.77%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$597M
AUM Growth
+$597M
(+20%)
Cap. Flow
+$37.8M
Cap. Flow
% of AUM
6.34%
Top 10 Holdings %
Top 10 Hldgs %
54.95%
Holding
336
New
84
Increased
76
Reduced
73
Closed
71
Top Buys
| 1 |
Immunovant
IMVT
|
$18.7M |
| 2 |
Ascendis Pharma
ASND
|
$16.4M |
| 3 |
Zura Bio
ZURA
|
$15.3M |
| 4 |
Zai Lab
ZLAB
|
$12.3M |
| 5 |
AAM
AA Mission Acquisition Corp.
AAM
|
$10.1M |
Top Sells
| 1 |
Protagonist Therapeutics
PTGX
|
$28M |
| 2 |
Roivant Sciences
ROIV
|
$13M |
| 3 |
Edgewise Therapeutics
EWTX
|
$11.2M |
| 4 |
Merck
MRK
|
$8.47M |
| 5 |
TECX
Tectonic Therapeutic, Inc. Common Stock
TECX
|
$6.96M |
Sector Composition
| 1 | Healthcare | 88.63% |
| 2 | Financials | 3.75% |
| 3 | Communication Services | 0.59% |
| 4 | Utilities | 0.21% |
| 5 | Technology | 0.17% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
OmniAb
OABI
$219M
| $5.66M | 0.92% |
1,337,302
+624,742
| +88% | +$2.64M |
|
27
CG Oncology
CGON
$2.19B
| $5.4M | 0.88% |
143,104
+130,254
| +1,014% | +$4.91M |
|
28
Crinetics Pharmaceuticals
CRNX
$3.26B
| $4.52M | 0.73% |
88,425
+13,575
| +18% | +$694K |
|
|
BBOT
29
BridgeBio Oncology Therapeutics, Inc. Common Stock
BBOT
$779M
| $4.22M | 0.69% |
404,138
| – | – |
|
|
TECX
30
Tectonic Therapeutic, Inc. Common Stock
TECX
$305M
| $3.85M | 0.63% |
127,159
-229,719
| -64% | -$6.96M |
|
|
ITOS
31
DELISTED
iTeos Therapeutics
ITOS
| $3.85M | 0.63% |
376,737
+316,737
| +528% | +$3.23M |
|
32
Absci
ABSI
$356M
| $3.84M | 0.62% |
1,005,750
-692,779
| -41% | -$2.65M |
|
|
EDR
33
DELISTED
Endeavor Group Holdings, Inc.
EDR
| $3.51M | 0.57% |
122,807
+112,192
| +1,057% | +$3.2M |
|
34
Apogee Therapeutics
APGE
$2.27B
| $3.36M | 0.55% |
57,183
+16,308
| +40% | +$958K |
|
35
Dianthus Therapeutics
DNTH
$781M
| $3.25M | 0.53% |
+118,738
| New | +$3.25M |
|
36
Savara
SVRA
$591M
| $3.15M | 0.51% |
742,634
+79,036
| +12% | +$335K |
|
37
Denali Therapeutics
DNLI
$2.24B
| $2.97M | 0.48% |
101,826
+63,826
| +168% | +$1.86M |
|
|
GRCE
38
Grace Therapeutics, Inc. Common Stock
GRCE
$41.1M
| $2.88M | 0.47% |
959,571
| – | – |
|
39
Q32 Bio
QTTB
$20.9M
| $2.87M | 0.47% |
64,245
-92,259
| -59% | -$4.12M |
|
40
Pliant Therapeutics
PLRX
$105M
| $2.76M | 0.45% |
246,128
+236,128
| +2,361% | +$2.65M |
|
41
Geron
GERN
$893M
| $2.53M | 0.41% |
557,159
+467,159
| +519% | +$2.12M |
|
|
PVLA
42
Palvella Therapeutics, Inc. Common Stock
PVLA
$592M
| $2.4M | 0.39% |
+144,641
| New | +$2.4M |
|
43
Vir Biotechnology
VIR
$765M
| $2.39M | 0.39% |
319,185
+209,185
| +190% | +$1.57M |
|
44
Cellectar Biosciences
CLRB
$15.3M
| $2.19M | 0.36% |
1,022,161
+340,067
| +50% | +$728K |
|
45
Alkermes
ALKS
$4.95B
| $2.08M | 0.34% |
74,431
-122,146
| -62% | -$3.42M |
|
46
Revolution Medicines
RVMD
$7.43B
| $2.01M | 0.33% |
+44,351
| New | +$2.01M |
|
47
SPDR Bloomberg 1-3 Month T-Bill ETF
BIL
$41.9B
| $2M | 0.33% |
21,786
-10,714
| -33% | -$984K |
|
48
Alector
ALEC
$282M
| $2M | 0.33% |
428,802
+233,491
| +120% | +$1.09M |
|
49
Teva Pharmaceuticals
TEVA
$21.5B
| $1.95M | 0.32% |
108,171
+5,050
| +5% | +$91K |
|
50
KALA BIO
KALA
$105M
| $1.74M | 0.28% |
306,067
| – | – |
|